Ocuphire Pharma Inc (NASDAQ:OCUP) saw a downside of -6.09% to $3.78 after subtracting -$0.24 on Wednesday. The 5-day average trading volume is 724,639 shares of the company’s common stock. It has gained $4.50 in the past week and touched a new high 3 times within the past 5 days. An average of 340,450 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 204,020.
OCUP’s 1-month performance is -5.39% or -$0.12 on its low of $3.60 reached on 09/27/23. The company’s shares have touched a 52-week low of $1.95 and high of $6.60, with the stock’s rally to the 52-week high happening on 05/11/23. YTD, OCUP has achieved 6.94% or $0.29 and has reached a new high 16 times. However, the current price is down -42.80% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
OCUP stock has a beta of 0.30. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.75 while the price-to-book (PB) in the most recent quarter is 2.10, with the price to cash flow ratio at 3.67.
Ocuphire Pharma Inc’s quick ratio for the period ended June 29 was 7.54, with the current ratio over the same period at 7.54. In terms of profitability, the gross margin trailing 12 months is 99.99%. The trailing 12-month EBITDA margin is 45.75% while for the period ending June 29, Ocuphire Pharma Inc’s operating margin was 40.09%. The firm’s gross profit as reported stood at $21.62 million against revenue of $39.85 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 0.6% to -$4.96 million, while revenue of -$5.79 million was -16.73% off the previous quarter. Analysts expected OCUP to announce -$0.23 per share in earnings in its latest quarter, but it posted -$0.24, representing a -4.30% surprise. EBITDA for the quarter stood at more than -$5.39 million. Shareholders hold equity totaling $21.01 million.
Let’s look briefly at Ocuphire Pharma Inc (OCUP) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 26 September was 39.48% to suggest the stock is trending Neutral, with historical volatility in this time period at 34.11%.
The stock’s 5-day moving average is $3.90, reflecting a -3.66% or -$0.14 change from its current price. OCUP is currently trading -3.66% above its 20-day SMA, -34.90% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -6.03% and SMA200 by+23.86%.
Stochastic %K and %D was 31.72% and 33.62% and the average true range (ATR) pointed at 0.24. The RSI (14) points at 42.28%, while the 14-day stochastic is at 23.89% with the period’s ATR at 0.22. The stock’s 9-day MACD Oscillator is pointing at -0.03 and -0.05 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for OCUP stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate OCUP as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 5 have offered a “buy” rating.
What is OCUP’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $17.00 and a high of $24.00, with their median price target at $20.00. Looking at these predictions, the average price target given by analysts is for Ocuphire Pharma Inc (OCUP) stock is $20.20.
